FindTrial
Sign In

CKD-702 Plus Irinotecan in Gastric Cancer

CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05750290
Enrollment
40
Registered
2023-03-01
Start date
2022-12-01
Completion date
2025-12-31
Last updated
2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Interventions

DRUGCKD-702 in combination with irinotecan

CKD-702 and irinotecan will be intravenously administered every 2 weeks.

Sponsors

National Cancer Center, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Failed 2 or more lines of chemotherapy * Tumor overexpressing either MET or EGFR * Measurable lesion

Exclusion criteria

* Prior treatment with anti-MET/EGFR bispecific antibody

Design outcomes

Primary

MeasureTime frameDescription
Best objective response rateThrough study completion, an average of 24 weeksRECIST v1.1

Countries

South Korea

Contacts

Primary ContactHark K Kim, MD,PhD
hkim@ncc.re.kr+82-31-920-2238

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026